Clinical Trial Update: Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the effect of tenofovir alafenamide fumarate on residual intrathecal immune activation in people with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids

Drugs mentioned

• Tenofovir alafenamide fumarate (tenofovir alafenamide fumarate)

Snippet

Sponsor: Göteborg University | Conditions: HIV | Phase 4 | Status: COMPLETED